MedTrace Logo

Enrichment of Glutathione Using Gamma-glutamylcysteine Supplementation in Parkinson's Disease Patients.

NCT07064005 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2026-05-04

No results posted yet for this study

Summary

This study is designed l to evaluate the effects of GGC oral supplementation in early Parkinson's disease (PD) patients. The main objectives of the study are to evaluate:

1. To study the enrichment of master antioxidant, glutathione (GSH) levels in brain and blood of these PD patients compared to baseline due to GGC supplementation.
2. To study the changes in motor function, cognitive skills in PD patients due to GGC oral supplementation
3. To study impact of GGC on gut health on the PD patients.

Conditions

  • Parkinsons Disease (PD)

Interventions

DRUG

Gamma- glutamylcysteine

400 mg (two times) per day

Sponsors & Collaborators

  • Waste Connections Inc

    collaborator UNKNOWN

  • Pravat Mandal

    lead OTHER

Principal Investigators

  • Pravat K Mandal, PHD · University of Pittsburgh

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-23
Primary Completion
2027-09-30
Completion
2027-11-27
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07064005 on ClinicalTrials.gov